Zhiqiang Qin
Concepts (327)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Herpesvirus 8, Human | 42 | 2024 | 90 | 19.000 |
Why?
| Sarcoma, Kaposi | 26 | 2023 | 72 | 12.990 |
Why?
| Lymphoma, Primary Effusion | 12 | 2023 | 18 | 6.100 |
Why?
| Virus Activation | 6 | 2022 | 30 | 3.360 |
Why?
| Endogenous Retroviruses | 3 | 2024 | 7 | 2.590 |
Why?
| Coinfection | 4 | 2024 | 36 | 2.420 |
Why?
| Host-Pathogen Interactions | 8 | 2020 | 143 | 2.390 |
Why?
| Oncogenic Viruses | 4 | 2021 | 17 | 2.240 |
Why?
| MicroRNAs | 12 | 2020 | 386 | 2.100 |
Why?
| Pyridines | 5 | 2018 | 137 | 2.090 |
Why?
| Viral Proteins | 8 | 2021 | 158 | 1.940 |
Why?
| Phosphotransferases (Alcohol Group Acceptor) | 5 | 2018 | 25 | 1.880 |
Why?
| Gene Expression Regulation, Viral | 9 | 2020 | 50 | 1.800 |
Why?
| Herpesviridae Infections | 6 | 2021 | 46 | 1.770 |
Why?
| Adamantane | 4 | 2018 | 33 | 1.700 |
Why?
| Virus Latency | 8 | 2023 | 46 | 1.690 |
Why?
| Gene Expression Regulation, Neoplastic | 8 | 2021 | 868 | 1.680 |
Why?
| Lung Neoplasms | 5 | 2022 | 643 | 1.660 |
Why?
| Ceramides | 4 | 2020 | 32 | 1.660 |
Why?
| Signal Transduction | 13 | 2022 | 1752 | 1.660 |
Why?
| Schistosomiasis japonica | 2 | 2023 | 2 | 1.630 |
Why?
| Gene Expression Regulation | 7 | 2019 | 1063 | 1.610 |
Why?
| Cell Line, Tumor | 16 | 2023 | 1551 | 1.510 |
Why?
| Humans | 69 | 2024 | 54391 | 1.510 |
Why?
| Carcinoma, Non-Small-Cell Lung | 4 | 2021 | 164 | 1.490 |
Why?
| Autoantibodies | 4 | 2023 | 135 | 1.490 |
Why?
| Amino Acid Transport System y+ | 3 | 2015 | 3 | 1.400 |
Why?
| Antiviral Agents | 2 | 2021 | 188 | 1.360 |
Why?
| Papillomavirus Infections | 2 | 2024 | 163 | 1.350 |
Why?
| Lymphoma | 3 | 2019 | 72 | 1.310 |
Why?
| Mouth | 3 | 2020 | 35 | 1.310 |
Why?
| Proto-Oncogene Proteins c-met | 3 | 2017 | 21 | 1.280 |
Why?
| Uterine Cervical Neoplasms | 2 | 2024 | 276 | 1.260 |
Why?
| HIV Infections | 5 | 2020 | 394 | 1.230 |
Why?
| Apoptosis | 13 | 2020 | 1302 | 1.150 |
Why?
| Epstein-Barr Virus Infections | 3 | 2022 | 35 | 1.050 |
Why?
| Cell Transformation, Viral | 2 | 2016 | 27 | 1.020 |
Why?
| Cell Proliferation | 10 | 2021 | 1097 | 1.000 |
Why?
| Interleukin-10 | 2 | 2018 | 106 | 0.980 |
Why?
| Oropharyngeal Neoplasms | 1 | 2024 | 14 | 0.960 |
Why?
| Animals | 25 | 2024 | 14409 | 0.960 |
Why?
| Histamine | 2 | 2023 | 28 | 0.960 |
Why?
| Mice | 17 | 2024 | 6428 | 0.950 |
Why?
| Anus Neoplasms | 1 | 2024 | 33 | 0.940 |
Why?
| Virus Diseases | 1 | 2024 | 44 | 0.930 |
Why?
| Echinomycin | 1 | 2023 | 7 | 0.920 |
Why?
| Neoplasms | 2 | 2024 | 1322 | 0.920 |
Why?
| Penile Neoplasms | 1 | 2024 | 43 | 0.920 |
Why?
| Cough | 1 | 2023 | 55 | 0.920 |
Why?
| Interferon Type I | 1 | 2023 | 30 | 0.890 |
Why?
| Herpesviridae | 2 | 2022 | 19 | 0.890 |
Why?
| Bacterial Proteins | 2 | 2020 | 456 | 0.880 |
Why?
| Human Umbilical Vein Endothelial Cells | 4 | 2019 | 95 | 0.860 |
Why?
| Nuclear Proteins | 5 | 2023 | 253 | 0.850 |
Why?
| Mycoses | 1 | 2023 | 162 | 0.850 |
Why?
| Small Cell Lung Carcinoma | 1 | 2022 | 27 | 0.830 |
Why?
| Sphingolipids | 2 | 2020 | 14 | 0.810 |
Why?
| Schistosoma japonicum | 2 | 2018 | 2 | 0.810 |
Why?
| Eukaryotic Initiation Factor-4G | 1 | 2021 | 4 | 0.790 |
Why?
| RNA, Viral | 4 | 2022 | 141 | 0.790 |
Why?
| Xenograft Model Antitumor Assays | 5 | 2021 | 219 | 0.780 |
Why?
| Brain Stem Neoplasms | 1 | 2020 | 4 | 0.750 |
Why?
| Drug Resistance, Neoplasm | 3 | 2019 | 309 | 0.750 |
Why?
| Antigens, Bacterial | 1 | 2020 | 63 | 0.740 |
Why?
| Antigens, Viral | 4 | 2016 | 58 | 0.740 |
Why?
| Cell Line | 9 | 2021 | 1152 | 0.740 |
Why?
| Gene Regulatory Networks | 1 | 2021 | 124 | 0.730 |
Why?
| Tumor Virus Infections | 1 | 2019 | 43 | 0.720 |
Why?
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2019 | 6 | 0.710 |
Why?
| Virus Replication | 5 | 2020 | 143 | 0.700 |
Why?
| Hepatocyte Growth Factor | 2 | 2016 | 14 | 0.700 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2020 | 87 | 0.700 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2019 | 40 | 0.690 |
Why?
| Helminth Proteins | 1 | 2018 | 2 | 0.670 |
Why?
| Antigens, Helminth | 1 | 2018 | 4 | 0.670 |
Why?
| Antibodies, Antinuclear | 1 | 2018 | 19 | 0.670 |
Why?
| Mycobacterium tuberculosis | 1 | 2020 | 212 | 0.660 |
Why?
| Antibodies, Protozoan | 1 | 2018 | 12 | 0.660 |
Why?
| 4-Butyrolactone | 1 | 2018 | 6 | 0.660 |
Why?
| Interleukin-12 | 1 | 2018 | 37 | 0.660 |
Why?
| Interleukin-17 | 1 | 2018 | 38 | 0.650 |
Why?
| Quorum Sensing | 1 | 2018 | 9 | 0.650 |
Why?
| Endothelium, Vascular | 3 | 2016 | 288 | 0.640 |
Why?
| Hyaluronic Acid | 2 | 2015 | 32 | 0.640 |
Why?
| Fibroblasts | 4 | 2016 | 386 | 0.640 |
Why?
| Quinolones | 1 | 2018 | 35 | 0.630 |
Why?
| Transcriptional Activation | 1 | 2018 | 134 | 0.630 |
Why?
| Tumor Microenvironment | 2 | 2016 | 210 | 0.620 |
Why?
| Papillomavirus E7 Proteins | 1 | 2017 | 33 | 0.610 |
Why?
| Tumor Cells, Cultured | 4 | 2020 | 477 | 0.610 |
Why?
| Oncogene Proteins, Viral | 1 | 2017 | 57 | 0.590 |
Why?
| Mice, SCID | 5 | 2020 | 196 | 0.590 |
Why?
| Herpesvirus 4, Human | 3 | 2022 | 39 | 0.580 |
Why?
| Trans-Activators | 2 | 2020 | 147 | 0.570 |
Why?
| Lipid Metabolism | 1 | 2017 | 194 | 0.560 |
Why?
| Heme Oxygenase-1 | 1 | 2016 | 21 | 0.560 |
Why?
| ADAM Proteins | 1 | 2016 | 24 | 0.550 |
Why?
| Repressor Proteins | 1 | 2017 | 165 | 0.540 |
Why?
| Piperidines | 1 | 2015 | 103 | 0.520 |
Why?
| Male | 18 | 2024 | 27347 | 0.510 |
Why?
| Acquired Immunodeficiency Syndrome | 1 | 2015 | 66 | 0.510 |
Why?
| Teichoic Acids | 1 | 2014 | 8 | 0.500 |
Why?
| Gene Expression Profiling | 5 | 2020 | 1141 | 0.500 |
Why?
| Virus Internalization | 1 | 2014 | 20 | 0.500 |
Why?
| Lymphoma, AIDS-Related | 1 | 2014 | 24 | 0.490 |
Why?
| Up-Regulation | 6 | 2020 | 509 | 0.470 |
Why?
| Cell Cycle Checkpoints | 3 | 2020 | 35 | 0.470 |
Why?
| Endothelial Cells | 4 | 2024 | 294 | 0.470 |
Why?
| Middle Aged | 12 | 2023 | 13082 | 0.460 |
Why?
| Mice, Inbred NOD | 4 | 2020 | 99 | 0.460 |
Why?
| Lipopolysaccharides | 1 | 2014 | 200 | 0.460 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2017 | 674 | 0.460 |
Why?
| Dual Specificity Phosphatase 1 | 1 | 2012 | 10 | 0.450 |
Why?
| Cell Survival | 4 | 2021 | 657 | 0.440 |
Why?
| Staphylococcus epidermidis | 1 | 2012 | 16 | 0.430 |
Why?
| Catheters, Indwelling | 1 | 2012 | 68 | 0.420 |
Why?
| Receptors, Histamine | 2 | 2023 | 7 | 0.420 |
Why?
| Female | 15 | 2024 | 28471 | 0.410 |
Why?
| Neoplasm Invasiveness | 5 | 2019 | 294 | 0.410 |
Why?
| Cells, Cultured | 4 | 2020 | 1737 | 0.400 |
Why?
| Antineoplastic Agents | 2 | 2019 | 1300 | 0.400 |
Why?
| NM23 Nucleoside Diphosphate Kinases | 1 | 2011 | 5 | 0.400 |
Why?
| Autoantigens | 2 | 2023 | 64 | 0.390 |
Why?
| Young Adult | 5 | 2020 | 4318 | 0.380 |
Why?
| Mitogen-Activated Protein Kinases | 2 | 2011 | 170 | 0.380 |
Why?
| Cell Cycle Proteins | 2 | 2023 | 198 | 0.370 |
Why?
| Monocytes | 2 | 2017 | 156 | 0.370 |
Why?
| Biofilms | 1 | 2012 | 202 | 0.370 |
Why?
| Interferons | 2 | 2023 | 44 | 0.370 |
Why?
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2010 | 4 | 0.370 |
Why?
| Gene Expression Regulation, Bacterial | 1 | 2012 | 246 | 0.370 |
Why?
| High-Throughput Screening Assays | 2 | 2020 | 37 | 0.360 |
Why?
| Macrophages | 2 | 2010 | 404 | 0.360 |
Why?
| HSP90 Heat-Shock Proteins | 1 | 2010 | 53 | 0.360 |
Why?
| Cell Movement | 5 | 2020 | 271 | 0.360 |
Why?
| Epithelial-Mesenchymal Transition | 3 | 2019 | 53 | 0.360 |
Why?
| RNA Interference | 5 | 2016 | 195 | 0.360 |
Why?
| Immunoblotting | 3 | 2015 | 134 | 0.350 |
Why?
| Adult | 9 | 2020 | 14207 | 0.340 |
Why?
| Blotting, Western | 3 | 2017 | 684 | 0.340 |
Why?
| Down-Regulation | 3 | 2017 | 388 | 0.330 |
Why?
| Interleukin-6 | 1 | 2010 | 315 | 0.320 |
Why?
| RNA, Messenger | 4 | 2017 | 1203 | 0.320 |
Why?
| Staphylococcus aureus | 3 | 2020 | 363 | 0.310 |
Why?
| CD8-Positive T-Lymphocytes | 3 | 2024 | 116 | 0.310 |
Why?
| Fluorescent Antibody Technique | 3 | 2015 | 141 | 0.310 |
Why?
| HIV | 2 | 2019 | 26 | 0.310 |
Why?
| Disease Progression | 4 | 2021 | 915 | 0.310 |
Why?
| Hypertension | 2 | 2024 | 565 | 0.310 |
Why?
| Real-Time Polymerase Chain Reaction | 3 | 2017 | 206 | 0.300 |
Why?
| Transcription Factors | 2 | 2023 | 622 | 0.290 |
Why?
| Virulence Factors | 2 | 2020 | 94 | 0.280 |
Why?
| RNA, Small Interfering | 2 | 2016 | 253 | 0.270 |
Why?
| Cell Transformation, Neoplastic | 2 | 2023 | 200 | 0.260 |
Why?
| Mice, Nude | 4 | 2020 | 284 | 0.260 |
Why?
| Interferon-gamma | 2 | 2023 | 195 | 0.250 |
Why?
| Aged | 5 | 2020 | 10060 | 0.250 |
Why?
| Oncogene Proteins | 1 | 2024 | 17 | 0.240 |
Why?
| Oxidative Stress | 1 | 2010 | 958 | 0.240 |
Why?
| Endothelium, Lymphatic | 1 | 2024 | 13 | 0.240 |
Why?
| Disease Models, Animal | 3 | 2022 | 1647 | 0.240 |
Why?
| MAP Kinase Signaling System | 2 | 2015 | 133 | 0.240 |
Why?
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 474 | 0.240 |
Why?
| Immunocompromised Host | 2 | 2015 | 130 | 0.230 |
Why?
| Phosphorylation | 2 | 2017 | 613 | 0.230 |
Why?
| DNA Damage | 2 | 2016 | 357 | 0.230 |
Why?
| Jumonji Domain-Containing Histone Demethylases | 1 | 2023 | 18 | 0.230 |
Why?
| Cytokines | 2 | 2017 | 677 | 0.230 |
Why?
| Immunohistochemistry | 2 | 2021 | 1090 | 0.230 |
Why?
| Interferon-alpha | 1 | 2023 | 50 | 0.220 |
Why?
| Polymerase Chain Reaction | 3 | 2015 | 531 | 0.220 |
Why?
| DNA Repair | 1 | 2024 | 203 | 0.220 |
Why?
| Ultrasonography, Interventional | 1 | 2023 | 146 | 0.220 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2023 | 56 | 0.220 |
Why?
| Tubercidin | 1 | 2022 | 3 | 0.220 |
Why?
| Amaryllidaceae Alkaloids | 1 | 2022 | 3 | 0.220 |
Why?
| Phenanthridines | 1 | 2022 | 4 | 0.220 |
Why?
| Transaminases | 1 | 2022 | 14 | 0.210 |
Why?
| Adenosine Monophosphate | 1 | 2022 | 15 | 0.210 |
Why?
| Alanine | 1 | 2022 | 44 | 0.210 |
Why?
| Cell Cycle | 1 | 2023 | 275 | 0.210 |
Why?
| Benzamidines | 1 | 2021 | 6 | 0.200 |
Why?
| Azithromycin | 1 | 2021 | 42 | 0.200 |
Why?
| Guanidines | 1 | 2021 | 36 | 0.200 |
Why?
| Transfection | 2 | 2014 | 399 | 0.200 |
Why?
| Lymph Nodes | 1 | 2023 | 284 | 0.200 |
Why?
| HEK293 Cells | 2 | 2019 | 245 | 0.200 |
Why?
| Neoplasm Transplantation | 3 | 2019 | 94 | 0.200 |
Why?
| Structure-Activity Relationship | 2 | 2020 | 423 | 0.200 |
Why?
| Immune Evasion | 1 | 2021 | 12 | 0.200 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 2021 | 63 | 0.190 |
Why?
| Ubiquitin | 1 | 2020 | 51 | 0.190 |
Why?
| Interleukin-1 | 1 | 2020 | 107 | 0.190 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2020 | 142 | 0.180 |
Why?
| Immunotherapy | 1 | 2022 | 264 | 0.180 |
Why?
| Tumor Escape | 1 | 2019 | 20 | 0.180 |
Why?
| Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 314 | 0.180 |
Why?
| Drug Evaluation, Preclinical | 1 | 2019 | 158 | 0.170 |
Why?
| Molecular Structure | 1 | 2020 | 319 | 0.170 |
Why?
| Carcinoma, Renal Cell | 1 | 2020 | 120 | 0.170 |
Why?
| Homeodomain Proteins | 1 | 2019 | 82 | 0.170 |
Why?
| Interleukin-1beta | 1 | 2019 | 92 | 0.170 |
Why?
| Bacterial Load | 1 | 2018 | 13 | 0.170 |
Why?
| Transplantation, Heterologous | 2 | 2019 | 76 | 0.160 |
Why?
| Dose-Response Relationship, Drug | 2 | 2020 | 1476 | 0.160 |
Why?
| Autoimmunity | 1 | 2018 | 38 | 0.160 |
Why?
| Kidney Neoplasms | 1 | 2020 | 197 | 0.160 |
Why?
| HIV-1 | 1 | 2018 | 72 | 0.160 |
Why?
| Pseudomonas Infections | 1 | 2018 | 54 | 0.160 |
Why?
| Cell Growth Processes | 1 | 2018 | 24 | 0.160 |
Why?
| Neovascularization, Pathologic | 1 | 2019 | 168 | 0.160 |
Why?
| Pseudomonas aeruginosa | 1 | 2018 | 86 | 0.160 |
Why?
| Microscopy, Electron | 1 | 2017 | 97 | 0.150 |
Why?
| Virulence | 1 | 2018 | 196 | 0.150 |
Why?
| Sphingosine | 2 | 2015 | 27 | 0.150 |
Why?
| Lysophospholipids | 2 | 2015 | 34 | 0.150 |
Why?
| Random Allocation | 1 | 2018 | 312 | 0.150 |
Why?
| Pandemics | 1 | 2022 | 594 | 0.150 |
Why?
| Toll-Like Receptor 2 | 1 | 2017 | 29 | 0.150 |
Why?
| Exons | 1 | 2017 | 105 | 0.150 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2018 | 181 | 0.150 |
Why?
| Exoribonucleases | 1 | 2016 | 4 | 0.150 |
Why?
| Exonucleases | 1 | 2016 | 7 | 0.150 |
Why?
| Lung | 1 | 2020 | 508 | 0.140 |
Why?
| Toll-Like Receptor 4 | 1 | 2017 | 51 | 0.140 |
Why?
| Tuberculosis, Pulmonary | 1 | 2017 | 85 | 0.140 |
Why?
| Pleural Effusion | 1 | 2017 | 38 | 0.140 |
Why?
| Ubiquitins | 1 | 2016 | 40 | 0.140 |
Why?
| Protoporphyrins | 1 | 2016 | 6 | 0.140 |
Why?
| Receptors, Cell Surface | 1 | 2017 | 130 | 0.140 |
Why?
| Metalloporphyrins | 1 | 2016 | 13 | 0.140 |
Why?
| Molluscacides | 1 | 2015 | 1 | 0.140 |
Why?
| Salicylanilides | 1 | 2015 | 1 | 0.140 |
Why?
| Protein Kinase Inhibitors | 1 | 2018 | 216 | 0.140 |
Why?
| Gastropoda | 1 | 2015 | 4 | 0.140 |
Why?
| Comet Assay | 1 | 2015 | 17 | 0.140 |
Why?
| Anthelmintics | 1 | 2015 | 11 | 0.140 |
Why?
| Base Sequence | 1 | 2017 | 719 | 0.130 |
Why?
| Oxidoreductases | 1 | 2015 | 62 | 0.130 |
Why?
| Autophagy | 1 | 2017 | 202 | 0.130 |
Why?
| Necrosis | 1 | 2016 | 208 | 0.130 |
Why?
| Membrane Proteins | 1 | 2018 | 389 | 0.130 |
Why?
| Amino Acid Sequence | 1 | 2017 | 767 | 0.130 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 206 | 0.130 |
Why?
| Nerve Tissue Proteins | 1 | 2017 | 200 | 0.130 |
Why?
| Pyrazoles | 1 | 2015 | 110 | 0.130 |
Why?
| Cohort Studies | 1 | 2019 | 1546 | 0.130 |
Why?
| Porphyromonas gingivalis | 1 | 2014 | 3 | 0.130 |
Why?
| Transcriptome | 1 | 2017 | 346 | 0.130 |
Why?
| Glutamates | 1 | 2014 | 22 | 0.120 |
Why?
| Cystine | 1 | 2014 | 15 | 0.120 |
Why?
| Mice, Inbred BALB C | 3 | 2020 | 370 | 0.120 |
Why?
| Lymphocytes | 2 | 2017 | 168 | 0.120 |
Why?
| Glucuronosyltransferase | 1 | 2015 | 157 | 0.120 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1060 | 0.110 |
Why?
| Sodium Chloride, Dietary | 2 | 2024 | 33 | 0.110 |
Why?
| Sodium | 2 | 2024 | 102 | 0.110 |
Why?
| Molecular Targeted Therapy | 1 | 2013 | 128 | 0.110 |
Why?
| Flow Cytometry | 1 | 2015 | 547 | 0.110 |
Why?
| Bacteriolysis | 1 | 2012 | 4 | 0.110 |
Why?
| Bacterial Adhesion | 1 | 2012 | 20 | 0.110 |
Why?
| NF-kappa B | 1 | 2014 | 336 | 0.110 |
Why?
| RNA, Bacterial | 1 | 2012 | 58 | 0.110 |
Why?
| Mouth Neoplasms | 1 | 2011 | 25 | 0.100 |
Why?
| Reactive Oxygen Species | 1 | 2014 | 491 | 0.100 |
Why?
| DNA, Bacterial | 1 | 2012 | 172 | 0.100 |
Why?
| Cross Infection | 1 | 2012 | 109 | 0.100 |
Why?
| Bacteremia | 1 | 2012 | 104 | 0.100 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2011 | 232 | 0.090 |
Why?
| Cytopathogenic Effect, Viral | 1 | 2010 | 5 | 0.090 |
Why?
| Aged, 80 and over | 1 | 2018 | 3431 | 0.090 |
Why?
| Colony-Forming Units Assay | 1 | 2010 | 31 | 0.090 |
Why?
| Basic-Leucine Zipper Transcription Factors | 1 | 2010 | 16 | 0.090 |
Why?
| Reactive Nitrogen Species | 1 | 2010 | 37 | 0.090 |
Why?
| 3' Untranslated Regions | 1 | 2010 | 57 | 0.090 |
Why?
| Cell Adhesion | 1 | 2010 | 171 | 0.090 |
Why?
| Protein Isoforms | 1 | 2010 | 124 | 0.090 |
Why?
| Staphylococcal Infections | 1 | 2012 | 302 | 0.090 |
Why?
| Neoplasm Metastasis | 2 | 2020 | 252 | 0.090 |
Why?
| Neoplasm Staging | 1 | 2010 | 805 | 0.070 |
Why?
| Adolescent | 1 | 2018 | 6900 | 0.070 |
Why?
| Child | 1 | 2018 | 7368 | 0.070 |
Why?
| Protein Binding | 2 | 2020 | 736 | 0.070 |
Why?
| Receptors, Purinergic P2X7 | 1 | 2024 | 6 | 0.060 |
Why?
| Receptors, Interleukin-1 | 1 | 2022 | 20 | 0.060 |
Why?
| Adenosine Triphosphate | 1 | 2024 | 242 | 0.050 |
Why?
| Adaptive Immunity | 1 | 2022 | 39 | 0.050 |
Why?
| Sodium Chloride Symporters | 1 | 2022 | 5 | 0.050 |
Why?
| Kidney Tubules, Distal | 1 | 2022 | 17 | 0.050 |
Why?
| Mice, Knockout | 1 | 2024 | 927 | 0.050 |
Why?
| Neovascularization, Physiologic | 1 | 2021 | 72 | 0.050 |
Why?
| Genome, Viral | 1 | 2020 | 100 | 0.050 |
Why?
| Proportional Hazards Models | 1 | 2021 | 430 | 0.050 |
Why?
| Phenotype | 2 | 2014 | 819 | 0.040 |
Why?
| Vimentin | 1 | 2019 | 33 | 0.040 |
Why?
| Cadherins | 1 | 2019 | 72 | 0.040 |
Why?
| CD4 Lymphocyte Count | 1 | 2018 | 35 | 0.040 |
Why?
| Bacterial Translocation | 1 | 2018 | 23 | 0.040 |
Why?
| Survival Rate | 1 | 2021 | 954 | 0.040 |
Why?
| Mice, Inbred C57BL | 1 | 2024 | 2001 | 0.040 |
Why?
| Promoter Regions, Genetic | 1 | 2020 | 520 | 0.040 |
Why?
| Oxygen | 1 | 2020 | 361 | 0.040 |
Why?
| Niclosamide | 1 | 2015 | 1 | 0.030 |
Why?
| Parasitic Sensitivity Tests | 1 | 2015 | 2 | 0.030 |
Why?
| Acetylcholinesterase | 1 | 2015 | 21 | 0.030 |
Why?
| L-Lactate Dehydrogenase | 1 | 2015 | 79 | 0.030 |
Why?
| Inhibitory Concentration 50 | 1 | 2015 | 80 | 0.030 |
Why?
| Esters | 1 | 2015 | 25 | 0.030 |
Why?
| Prognosis | 1 | 2021 | 2126 | 0.030 |
Why?
| Zebrafish | 1 | 2015 | 58 | 0.030 |
Why?
| Nitric Oxide Synthase | 1 | 2015 | 102 | 0.030 |
Why?
| Case-Control Studies | 1 | 2018 | 1229 | 0.030 |
Why?
| Primary Cell Culture | 1 | 2014 | 65 | 0.030 |
Why?
| Monocarboxylic Acid Transporters | 1 | 2014 | 4 | 0.030 |
Why?
| Membrane Microdomains | 1 | 2014 | 15 | 0.030 |
Why?
| Mutation | 1 | 2020 | 1504 | 0.030 |
Why?
| Vesicular Transport Proteins | 1 | 2014 | 43 | 0.030 |
Why?
| Molecular Typing | 1 | 2012 | 10 | 0.030 |
Why?
| Molecular Epidemiology | 1 | 2012 | 36 | 0.030 |
Why?
| China | 1 | 2012 | 104 | 0.030 |
Why?
| Microbial Sensitivity Tests | 1 | 2012 | 290 | 0.030 |
Why?
| Hospitals | 1 | 2012 | 188 | 0.020 |
Why?
| Enzyme Activation | 1 | 2011 | 328 | 0.020 |
Why?
| Genotype | 1 | 2012 | 600 | 0.020 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 176 | 0.020 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 153 | 0.020 |
Why?
| Anti-Bacterial Agents | 1 | 2012 | 825 | 0.020 |
Why?
|
|
Qin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|